Cargando…
Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer
BACKGROUND: Recent advances in targeted therapies have raised expectations that the clinical application of biomarkers would improve patient’s health outcomes and potentially save costs. However, the cost-effectiveness of biomarkers remains unclear irrespective of the cost-effectiveness of correspon...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157891/ https://www.ncbi.nlm.nih.gov/pubmed/30256829 http://dx.doi.org/10.1371/journal.pone.0204496 |